Diverticular disease: A therapeutic overview

doi:10.4292/wjgpt.v1.i1.27

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9243)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

680

HTML

7565

Figures (1-1)

439

Tables (1-3)

559

Sum=9243

Feb 6, 2010 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Pharmacol Ther. Feb 6, 2010; 1(1): 27-35
Published online Feb 6, 2010. doi: 10.4292/wjgpt.v1.i1.27

Full Size Figure Download Figure

Figure 1 Rationale for treating diverticular disease with mesalazine and/or probiotics. IgA: Immunoglobulin A; IFN: Interferon; IL: Interleukin; TNF: Tumour necrosis factor; COX: Cyclooxygenase; TBX: Thromboxane; PAF: Platelet activating factor.

Citation: Tursi A. Diverticular disease: A therapeutic overview. World J Gastrointest Pharmacol Ther 2010; 1(1): 27-35
URL: https://www.wjgnet.com/2150-5349/full/v1/i1/27.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v1.i1.27